|
Migraine, one of the neurological conditions, affects approximately 15% of the global population.
It is characterized by intense headaches accompanied by nausea, vomiting, and heightened
sensitivity to light. The first line of drugs for treating migraine are non-steroidal anti-inflammatory
drugs. Unfortunately, these medications suffer from poor solubility in water, uncontrolled release,
and numerous adverse side effects. In order to maximize their therapeutic effect by preventing
premature release and degradation, novel drug delivery systems based on composites are being
dynamically developed. Herein, the biocompatible ketoprofen (K), naproxen sodium (NS), and
diclofenac sodium (DS) vehicles integrating ordered mesoporous silica (SBA-16) with Fe-based
metal–organic frameworks (MIL-101(Fe)) were synthesized via the solvothermal method. The
composites were characterized by different percentages of MIL-101(Fe) (25 and 50 wt.%), which
had a significant impact on their porosity, structure, and number of functional groups. The
SBA-16@MIL-101(Fe)-25 and SBA-16@MIL-101(Fe)-50 samples exhibited BET surface areas of
768 and 324 m2 g−1, respectively. Their sorption capacities towards selected anti-inflammatory
drugs were in the range of 141–318 mg g−1 for K, 481–490 mg g−1 for NS, and 246–589 mg g−1 for
DS, notably exceeding the values obtained for pure mesoporous silica (5–9 mg g−1).
Morphological defects and specific functional groups, derived from SBA-16 and MIL-101(Fe),
contributed to generating new adsorption sites in composites, enhancing host-guest interactions.
The drug release profiles were determined by the carrier porosity, surface charge, and the presence
of functional groups. The diffusion of K and DS from the composites into the phosphate buffer
(pH 7.7), mimicking rectal fluid, occurred in a more controlled manner compared to pristine
silica. The SBA-16@MIL-101(Fe)-50 carrier released 82% of K and 90% of DS over 24 h.
|
